Welcome


Welcome to BioSentinel Pharmaceuticals!

• BioSentinel Pharmaceuticals
      BioSentinel's mission is the development of innovative tools and reagents for the study of botulinum neurotoxin (BoNT). Using technology licensed from the Wisconsin Alumni Research Foundation (WARF) and based on the work from the University of Wisconsin, our lab in the University Research Park has been creating technology advancements for improved BoNT research and detection since mid-2007.

      We believe our tests and assays are setting a new standard for speed, accuracy, and low cost. BoTest™ A/E BoNT Detection Kit, our first product, is an in vitro assay (For non-clinical research purposes only) that can be used in low or high throughput formats using standard fluorescent plate readers. We look forward to taking your orders, answering your questions, and furthering your research.


• Future Releases
      Please watch this space on our website for information about the future release of BoTest™ B/D/F/G, an in vitro assay for BoNT/B, D, F and G; BoCell™ A, a cell-based assay for botulinum; and other products in our development pipeline.

 Recent News:
WARF Start-up BioSentinel Launches Second Product for “Real Time” Detection of Deadly Botulinum Toxins (January 12, 2010)
http://www.biosentinelpharma.com/news.php


MADISON, WI – BioSentinel Pharmaceuticals, a start-up biodefense company founded in 2007 and based on University of Wisconsin-Madison technology licensed from the Wisconsin Alumni Research Foundation (WARF), has released its second product, BoTest™ B/D/F/G Botulinum Neurotoxin Kit (BoTest™ B... [read more]
BioSentinel to present at 2009 IBRCC Conference (October 14, 2009)
http://www.biosentinelpharma.com/news.php


MADISON – BioSentinel will be presenting at the 2009 IBRCC Conference in Alexandria, VA on October 18-23. Presentations and posters on BioSentinel’s latest assay technologies, including information on the upcoming BoTest™ B/D/F biochemical assay for the detection of BoNT B/D/F proteolytic ... [read more]
BioSentinel releases “real-time” detection test for deadly strains of botulinum toxins (April 28, 2009)
http://www.biosentinelpharma.com/news.php


MADISON – A breakthrough test to rapidly and accurately detect small amounts of the most deadly strains of botulinum toxin has been released by BioSentinel Pharmaceuticals LLC, a Madison-based company.

The company’s new “BoTest”™ offers nearly a 300-fold increase in sensitivity ... [read more]